and OGXI has 427 several years away from FDA approval but only a year or two away from proof of concept Postrate, Bladder, ect.........
If 427 works in Postrate, Bladder, ect via P2 proof of concept trials. I still maintain that the stock is worth mid $30's PPS valuation. Just look at other oncology plays like ARIA. SGEN,
OGXI has explosive upside potential and we all know as the positive trial data flows the analyst PT's go up up up.
Merry XMASS to all and buy some REGULUS in 2013
Sentiment: Strong Buy